July 27, 2026

AstraZeneca Q2 and Elecoglipron Phase 3 Launch, TGA GLP-1 NAION Warning, AIDS 2026 Main Opens

AstraZeneca Q2 beats + elecoglipron Phase 3 kickoff. AIDS 2026 opens. Australia TGA GLP-1 NAION warning. Hims $440M peptide analyst perspective.

4 stories · Covering clinical-trials, regulatory, industry

Editor's Note

Monday's peptide news anchors on AstraZeneca's Q2 2026 earnings report before market open, which paired a top-line and bottom-line consensus beat (core EPS $2.63 +18% constant currency, revenue $15.38 billion +5%) with a substantive pipeline advance: elecoglipron, the oral small-molecule GLP-1 receptor agonist AstraZeneca in-licensed and progressed through Phase 2 VISTA and SOLSTICE with ADA 2026 data, has moved into a full Phase 3 program in Q2 across the EMBOLD obesity trials, the ELUMINATE type 2 diabetes trials (including combination with dapagliflozin), and cardiovascular and kidney outcome studies. AstraZeneca is now the third major sponsor competing with Novo Nordisk and Eli Lilly for the oral GLP-1 market. Away from earnings, the 26th International AIDS Conference (AIDS 2026) main conference opens Monday July 27 at Riocentro in Rio de Janeiro with the UNAIDS 'United to End AIDS' 2025 data report release documenting the severity of 2025 HIV funding cuts and the WHO's first global mid-term assessment of progress under the Global Health Sector Strategies (halfway point to the 2030 targets). Australia's Therapeutics Goods Administration (TGA) issued a class-wide GLP-1 receptor agonist product warning update on non-arteritic anterior ischaemic optic neuropathy (NAION) risk, with the Advisory Committee on Medicines concluding the evidence signal supports semaglutide (23 cases) but not dulaglutide or tirzepatide (10 cases). Post-PCAC analyst coverage of Hims & Hers Health (NYSE: HIMS) split, with BofA at $36 and Canaccord at $40 on the peptide opportunity while the 6-18 month FDA rulemaking timeline tempers the near-term catalyst.

Clinical Trials

AstraZeneca (NYSE: AZN) Reports Q2 2026 Earnings Before Market Open Monday July 27, 2026 With Core EPS of $2.63 (+18% Constant Currency, Beating $2.48 Consensus) on Revenue of $15.38 Billion (+5%, In Line With $15.39 Billion Consensus) and Advances Elecoglipron (Oral Small-Molecule GLP-1 Receptor Agonist) Into the Full Phase 3 Program in Q2 Across the EMBOLD Obesity Trials, the ELUMINATE Type 2 Diabetes Trials (Including Monotherapy and Combination With Dapagliflozin), and Cardiovascular and Kidney Outcome Trials Positioning AstraZeneca to Challenge Novo Nordisk and Eli Lilly in the Oral GLP-1 Market Alongside the Positive Q2 Update on Tozorakimab (Peak Sales Now Projected Above $5 Billion, Raised From $3 Billion)

AstraZeneca (NYSE: AZN) reported Q2 2026 earnings before market open Monday July 27, 2026 with core earnings per share of $2.63 for the three months ended June 30 (+18% constant currency), beating consensus of $2.48. Revenue of $15.38 billion was in line with consensus of $15.39 billion (+5%). Analyst focus on the earnings call centered on the pipeline update: elecoglipron, the oral small-molecule GLP-1 receptor agonist AstraZeneca in-licensed and advanced through Phase 2 VISTA and SOLSTICE (positive data at ADA 2026 Scientific Sessions in June), has moved into a full Phase 3 program in Q2 2026. The Phase 3 program includes the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca is now the third major sponsor competing with Novo Nordisk and Eli Lilly for the oral GLP-1 market alongside oral semaglutide/Ozempic and orforglipron (Foundayo, FDA-approved April 2026). AstraZeneca separately revised the peak sales projection for tozorakimab (experimental respiratory treatment) to above $5 billion from the previous $3 billion estimate. AZN shares rose approximately 1.7% in London Monday morning trading.

#astrazeneca #azn #q2-2026-earnings #elecoglipron #oral-glp-1 #embold #eluminate #dapagliflozin #phase-3 #cardiovascular-outcomes #tozorakimab

Clinical Trials

26th International AIDS Conference (AIDS 2026) Main Conference Opens Monday July 27, 2026 at Riocentro in Rio de Janeiro Brazil (Opening Ceremony 15:00-16:30 Local Time in the Global Village) With Release of the UNAIDS 'United to End AIDS' 2025 Data Report Documenting the Severity of 2025 HIV Funding Cuts and the WHO's First Global Mid-Term Assessment of Progress Under the Global Health Sector Strategies on HIV Viral Hepatitis and Sexually Transmitted Infections Marking the Halfway Point to the 2030 Targets — Peptide-Adjacent HIV Modality Content This Week Includes Gilead Sciences Lenacapavir PURPOSE 1 and PURPOSE 2 Long-Term Extension Data and Gilead-Merck Islatravir/Lenacapavir Phase 3 ISLEND-1 and ISLEND-2 Late-Breaker Wednesday July 29

The 26th International AIDS Conference (AIDS 2026) main conference opened Monday July 27, 2026 at Riocentro in Rio de Janeiro, Brazil. The opening ceremony ran 15:00-16:30 local time in the Global Village. UNAIDS released its 'United to End AIDS' 2025 data report on the opening day, documenting the severity of 2025 HIV funding cuts and their impact on HIV prevention, community services, key populations, and the sustainability of the global AIDS response. The WHO launched its first global mid-term assessment of progress under the Global Health Sector Strategies on HIV, viral hepatitis, and sexually transmitted infections, marking the halfway point to the 2030 targets and providing a comprehensive overview of where the world stands on the SDG 3.3 targets. Peptide-adjacent HIV modality content this week includes Gilead Sciences's twice-yearly lenacapavir (first-in-class HIV capsid inhibitor) PURPOSE 1 and PURPOSE 2 long-term extension data and the Gilead-Merck once-weekly oral islatravir/lenacapavir Phase 3 ISLEND-1 and ISLEND-2 detailed data late-breaker scheduled for Wednesday July 29. Merck plans separate presentations across daily, weekly, and monthly HIV treatment and prevention pipeline including alimatravir (MK-8527), the investigational once-monthly oral HIV prevention pill licensed July 24 to Aspen Pharmacare and six other generic manufacturers for 129 low- and middle-income countries.

#aids-2026 #unaids #who #hiv #hiv-funding-cuts #global-health-sector-strategies #2030-targets #lenacapavir #islend-1 #islend-2 #gilead #merck #rio-de-janeiro

Regulatory

Australia's Therapeutics Goods Administration (TGA) Issues Class-Wide GLP-1 Receptor Agonist Product Warning Update on July 25, 2026 for Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION), Adding Label Language Across Trulicity (Dulaglutide), Ozempic (Semaglutide), Wegovy (Semaglutide), Mounjaro (Tirzepatide), and Saxenda (Liraglutide) After the Advisory Committee on Medicines Concluded the Current Evidence Supports the Signal for Semaglutide but Not for Dulaglutide or Tirzepatide; 36 Total Cases of Optic Ischaemic Neuropathy Reported to the Australian Database of Adverse Event Notifications (DAEN) Including 23 for Semaglutide, 10 for Tirzepatide, and 3 for Liraglutide, With Patient Guidance to Seek Urgent Medical Attention for Sudden Vision Loss

Australia's Therapeutics Goods Administration (TGA) issued a class-wide product warning update Saturday July 25, 2026 for GLP-1 receptor agonists on non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but severe form of eye disorder that may result in permanent visual impairment including blindness. No treatment has been shown to improve visual acuity outcomes after NAION onset. The label update applies across all five GLP-1 RA products currently marketed in Australia: Trulicity (dulaglutide, Eli Lilly), Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk), Mounjaro (tirzepatide, Eli Lilly), and Saxenda (liraglutide, Novo Nordisk). The Advisory Committee on Medicines concluded that the current evidence supports the signal for semaglutide but not for dulaglutide or tirzepatide. A search of the Australian Database of Adverse Event Notifications (DAEN) found 36 cases of optic ischaemic neuropathy with GLP-1 RAs, including 23 for semaglutide, 10 for tirzepatide, and 3 for liraglutide. Patient guidance advises seeking urgent medical attention for any sudden vision loss including partial loss of vision. The Australian action follows the UK MHRA Drug Safety Update on semaglutide and NAION issued February 5, 2026.

#tga #australia #glp-1 #naion #semaglutide #tirzepatide #dulaglutide #liraglutide #ozempic #wegovy #mounjaro #trulicity #saxenda #eye-safety #pharmacovigilance

Industry

Post-PCAC Analyst Perspective on Hims & Hers Health (NYSE: HIMS): BofA Securities Raised Price Target to $36 and Canaccord Genuity Raised to $40 on the Peptide-Compounding Opportunity Estimated at Approximately $440 Million in 2027 Sales From the Four Recommended Compounding Peptides, While Truist Held at $23 Citing the 6-18 Month FDA Rulemaking Timeline and Uninsured-Patient Concerns; Peptide Catalyst Lift Tempered by the Advisory-Vote Nature of the July 23-24 PCAC 6-of-7 Outcome Because Compounding Pharmacies Still Cannot Legally Prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon Under Section 503A Today

Post-PCAC analyst coverage of Hims & Hers Health (NYSE: HIMS) split on the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 outcome. BofA Securities raised its price target to $36 on the peptide-compounding opportunity, and Canaccord Genuity raised to $40, both citing the July 23-24 PCAC vote and the Hims & Hers acquired California peptide manufacturing facility. Analysts estimate the four Day-1 recommended peptides (BPC-157, KPV, TB-500, MOTS-c) could generate approximately $440 million in Hims & Hers sales by 2027 if the FDA follows through with 503A rulemaking. Truist Securities held at $23 citing the 6-18 month FDA rulemaking timeline and continued uninsured-patient exposure. Barclays sits at $39 (Novo Nordisk partnership thesis). The peptide catalyst lift is tempered by the advisory-vote nature of the PCAC outcome: compounding pharmacies still cannot legally prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon under Section 503A today because none of the six substances are on the 503A Bulks List. FDA rulemaking to add each substance takes 6-18 months from the date the agency decides to act. Hims shares closed near $28.50 last week after briefly rallying above $35 on the initial vote outcome.

#hims-hers #hims #post-pcac #analyst-perspective #bofa #canaccord #truist #barclays #peptide-opportunity #440-million #rulemaking-timeline #peptide-compounding